Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 3 years, the average EBITDA Per Share Growth Rate was 36.50% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 33.40% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 12.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 12 years, the highest 3-Year average EBITDA Per Share Growth Rate of Solasia Pharma KK was 50.30% per year. The lowest was -35.90% per year. And the median was -1.40% per year.
Solasia Pharma KK (TSE:4597) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Solasia Pharma KK 3-Year EBITDA Growth Rate Related Terms
TSE:4597 vs ZTS: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Solasia Pharma KK's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Solasia Pharma KK 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Solasia Pharma KK's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Solasia Pharma KK's 3-Year EBITDA Growth Rate falls into.
Solasia Pharma KK 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 36.50% mean?
Solasia Pharma KK (TSE:4597) has a 3-Year EBITDA Growth Rate of 36.50% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Solasia Pharma KK and its competitors. According to the industry distribution chart, Solasia Pharma KK ranks #139 out of 808 companies in the Drug Manufacturers industry, placing it in the top 17.2%.
Is Solasia Pharma KK's 3-Year EBITDA Growth Rate too high?
Solasia Pharma KK's current 3-Year EBITDA Growth Rate is 36.50%. The Drug Manufacturers industry median 3-Year EBITDA Growth Rate is 8.90. Solasia Pharma KK's value of 36.50% is 310.1% above this industry median. Based on the distribution chart, Solasia Pharma KK ranks #139 out of 808 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Solasia Pharma KK has a GF Score™ of 71/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Solasia Pharma KK's 3-Year EBITDA Growth Rate compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Solasia Pharma KK ranks #139 out of 808 companies for 3-Year EBITDA Growth Rate. This places Solasia Pharma KK in the top 17% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 8.90. Solasia Pharma KK's value of 36.50% is 310.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.90, based on 808 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Solasia Pharma KK's current 3-Year EBITDA Growth Rate of 36.50% is 310.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Solasia Pharma KK and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Solasia Pharma KK's current 3-Year EBITDA Growth Rate is 36.50%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Solasia Pharma KK stock overvalued right now?
Based on GuruFocus' analysis, Solasia Pharma KK (TSE:4597) is currently considered Modestly Overvalued. The stock's GF Value™ is 円27.21, compared to a current price of 円31.00 — trading 13.9% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 36.50% and 310.1% above the Drug Manufacturers industry median of 8.90. Solasia Pharma KK's overall GF Score™ is 71/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Solasia Pharma KK (TSE:4597), the current 3-Year EBITDA Growth Rate is 36.50% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Solasia Pharma KK (TSE:4597) Overvalued in 2026?
Based on GuruFocus' analysis, Solasia Pharma KK stock appears to be overvalued.
The current stock price of 円31.00 is trading 13.9% above its estimated GF Value™ of 円27.21.
GuruFocus considers Solasia Pharma KK to be Modestly Overvalued.
Key valuation signals for TSE:4597:
3-Year EBITDA Growth Rate: 36.50%
GF Value™: 円27.21 vs. price of 円31.00 (13.9% above fair value)
Industry Position: 310.1% above the Drug Manufacturers median (#139 of 808)
No single metric tells the full story. See the TSE:4597 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4597 has been successfully added to your 
